| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T23347 | ||||
| Target Name | Interleukin-1 receptor, type II | ||||
| Target Type | Clinical Trial |
||||
| Action against Disease Model | AMG 108 | IL-1 receptor (IL-1R) blockage was highly efficacious in reducing inflammation, both in acute and advanced stages. In antigen-induced arthritis, cartilage damage, erosion progression, and propagation of inflammation are dependent on IL-1. In a recent study of immune complex arthritis, IL-1-deficient mice were strongly protected. In a novel transgenic mouse model of adjuvant arthritis, a pure T-cell model, mice deficient in the IL-1R antagonist displayed uncontrolled IL-1 activity and developed spontaneous T-cell-dependent autoimmune arthritis | [553074] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | We have used Balb/C Interleukin-1 receptor antagonist knock-out mice, which spontaneously develop RA-like disease in 100% of mice by 20 weeks of age to determine the n uMber of mesenchymal progenitors and their differentiated progeny before, at the start and with progression of the disease.Those data showed a decrease in the n uMber of mesenchymal progenitors with adipogenicpotential and decreased bone marrow adipogenesis before disease onset. This is associated with a decrease in osteoclastogenesis. Moreover, at the onset of disease a significant increase in all mesenchymal progenitors is observed together with a block in their differentiation to osteoblasts. This is associated with accelerated bone loss. | [553074] | |||
| References | |||||
| Ref 553074 | A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R192. doi: 10.1186/ar3163. Epub 2010 Oct 15. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.